GEn1E Lifesciences YCアプリケーション

Summer 2019Active

GEn1E LifesciencesはSummer 2019バッチでHealthcare企業としてY Combinatorを卒業しました。以下：会社の事業内容、創業者、そして実際のYCフォームで質問ごとに再構築されたYCへの応募内容。

YCバッチ: Summer 2019
業界: HealthcareTherapeutics
ステータス: Active
ローンチ済み: 2022

創業者

Ritu LalFounder

GEn1E Lifesciencesの事業内容

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

GEn1E LifesciencesのYCアプリケーション、再構築済み

Y Combinator 申請

GEn1E Lifesciences 様、Summer 2019 バッチ。公開データから回答された、実際のフォームの質問。

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

GEn1E Lifesciences

Describe what your company does in 50 characters or less.

AI platform accelerating therapies for rare diseases

What is your company going to make? Please describe your product and what it does or will do.

We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.

Where do you live now, and where would the company be based after YC?

We live in Palo Alto, CA, and the company is based here.

Explain your decision regarding location.

Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.

フルアプリケーションで21件の追加回答

はフルバージョンにあります。無料アカウントを作成して、他のすべてのYCバッチの横にあるYCインサイトで開いてください。

申請内容全体を見る

よくある質問

GEn1E Lifesciencesの実際のYCアプリケーションですか？

いいえ。Y Combinatorは提出されたアプリケーションを非公開にしています。これは再構築されたものです。実際のYCフォームの質問に、GEn1E Lifesciencesの公開データ（ローンチノート、創業者経歴、製品説明）から回答しています。GEn1E Lifesciencesのような会社がYCにどのようにアピールするかを示しており、彼らが提出したテキストではありません。